Anne-Virginie “AV” Eggimann Headshot

Anne-Virginie “AV” Eggimann

Chief Regulatory Officer

Anne-Virginie Eggimann joined Tessera in 2022 after leading the Regulatory Science function for nearly 11 years, most recently as Chief Regulatory Officer, at bluebird bio, Inc. As Tessera’s Chief Regulatory Officer, Anne-Virginie oversees several key functions responsible for driving forward the development of the company genome engineering products, including Regulatory Science, Program, Portfolio & Alliance Management, Program Leadership and Medical and Technical Writing. Ms. Eggimann is also responsible for Tessera’s Regulatory Intelligence & Policy activities.

Anne-Virginie has more than 20 years of experience in the development of innovative medicinal products, with a notable record of designing and executing robust regulatory strategies for bringing cell and gene therapies, oncology products and orphan drugs from early development to market.

Anne-Virginie is passionate about bringing innovative therapies to patients with significant unmet medical need. During her tenure at bluebird bio, she has played a key role in partnering with regulators to bring the company’s pioneering gene therapy products in severe genetic diseases and oncology from preclinical development to registration, leading to several recent approvals in Europe and the United States for Zynteglo and Skysona, as well as Abecma in partnership with Bristol Myers Squibb. Anne-Virginie has shaped bluebird’s regulatory policy efforts and is actively engaged with regulatory authorities and trade associations to continue to positively influence the evolving regulatory environment for the field of cell and gene therapy. Prior to joining bluebird, Anne-Virginie was an Executive Director at Voisin Consulting Life Sciences, leading complex development projects with biotech companies in both the United States and Europe. During her decade with VCLS, she contributed to the organization’s global growth from a handful of employees to more than seventy. Anne-Virginie currently serves on the board of Codiak Biosciences. She holds a Master of Science from the UCLA School of Public Health, and a B.S. in Chemical Engineering from the California Institute of Technology.